PL3571208T3 - Inhibitory immunoproteasomu - Google Patents

Inhibitory immunoproteasomu

Info

Publication number
PL3571208T3
PL3571208T3 PL18716009T PL18716009T PL3571208T3 PL 3571208 T3 PL3571208 T3 PL 3571208T3 PL 18716009 T PL18716009 T PL 18716009T PL 18716009 T PL18716009 T PL 18716009T PL 3571208 T3 PL3571208 T3 PL 3571208T3
Authority
PL
Poland
Prior art keywords
immunoproteasome inhibitors
immunoproteasome
inhibitors
Prior art date
Application number
PL18716009T
Other languages
English (en)
Inventor
Yan Lou
Timothy Duncan Owens
Kenneth Albert Brameld
David Michael Goldstein
Original Assignee
Principia Biopharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc. filed Critical Principia Biopharma Inc.
Publication of PL3571208T3 publication Critical patent/PL3571208T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
PL18716009T 2017-01-18 2018-01-16 Inhibitory immunoproteasomu PL3571208T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762447717P 2017-01-18 2017-01-18
US201762508771P 2017-05-19 2017-05-19
PCT/US2018/013823 WO2018136401A1 (en) 2017-01-18 2018-01-16 Immunoproteasome inhibitors
EP18716009.8A EP3571208B1 (en) 2017-01-18 2018-01-16 Immunoproteasome inhibitors

Publications (1)

Publication Number Publication Date
PL3571208T3 true PL3571208T3 (pl) 2021-09-20

Family

ID=61906812

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18716009T PL3571208T3 (pl) 2017-01-18 2018-01-16 Inhibitory immunoproteasomu

Country Status (19)

Country Link
US (1) US11154563B2 (pl)
EP (1) EP3571208B1 (pl)
JP (1) JP7071400B6 (pl)
KR (1) KR102534947B1 (pl)
CN (1) CN110248949B (pl)
AU (1) AU2018210839B2 (pl)
DK (1) DK3571208T3 (pl)
ES (1) ES2874638T3 (pl)
HR (1) HRP20210663T1 (pl)
HU (1) HUE054460T2 (pl)
LT (1) LT3571208T (pl)
MX (1) MX393757B (pl)
PL (1) PL3571208T3 (pl)
PT (1) PT3571208T (pl)
RS (1) RS61811B1 (pl)
SI (1) SI3571208T1 (pl)
TW (1) TWI821169B (pl)
UY (1) UY37569A (pl)
WO (1) WO2018136401A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3710457T3 (pl) 2017-11-16 2023-02-20 Principia Biopharma Inc. Inhibitory immunoproteasomu
WO2019099582A1 (en) 2017-11-16 2019-05-23 Principia Biopharma Inc. Immunoproteasome inhibitors
KR102993352B1 (ko) 2019-12-20 2026-07-22 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-에네니트릴의 고체 형태
CN113135943A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN116940580A (zh) * 2021-03-05 2023-10-24 Agc株式会社 化合物、化合物的制造方法及表面处理剂的制造方法
WO2024006337A1 (en) * 2022-06-30 2024-01-04 Principia Biopharma Inc. Cyclic boronic esters and their uses
US20250084085A1 (en) * 2023-08-01 2025-03-13 Principia Biopharma Inc. Process of making 2-[(3r)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enenitrile and solvate forms thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4963655A (en) 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
TWI345465B (en) * 2003-08-14 2011-07-21 Cephalon Inc Proteasome inhibitors and methods of using the same
AU2005216970B2 (en) * 2004-02-23 2011-07-07 Trustees Of Tufts College Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism
US10654843B2 (en) 2014-06-20 2020-05-19 Principia Biopharma Inc. LMP7 inhibitors
EP3201208B1 (en) * 2014-10-01 2021-03-24 Merck Patent GmbH Boronic acid derivatives
AU2015327345B9 (en) * 2014-10-01 2020-06-18 Merck Patent Gmbh Boronic acid derivatives
PL3710457T3 (pl) 2017-11-16 2023-02-20 Principia Biopharma Inc. Inhibitory immunoproteasomu
WO2019099582A1 (en) * 2017-11-16 2019-05-23 Principia Biopharma Inc. Immunoproteasome inhibitors

Also Published As

Publication number Publication date
HUE054460T2 (hu) 2021-09-28
JP2020506956A (ja) 2020-03-05
EP3571208A1 (en) 2019-11-27
LT3571208T (lt) 2021-05-25
ES2874638T3 (es) 2021-11-05
WO2018136401A1 (en) 2018-07-26
CA3049887A1 (en) 2018-07-26
KR20190104600A (ko) 2019-09-10
EP3571208B1 (en) 2021-03-10
JP7071400B6 (ja) 2022-06-07
TWI821169B (zh) 2023-11-11
JP7071400B2 (ja) 2022-05-18
SI3571208T1 (sl) 2021-06-30
AU2018210839A1 (en) 2019-07-25
PT3571208T (pt) 2021-04-13
MX2019008436A (es) 2019-09-18
KR102534947B1 (ko) 2023-05-23
AU2018210839B2 (en) 2022-01-20
RS61811B1 (sr) 2021-06-30
UY37569A (es) 2018-08-31
TW201831446A (zh) 2018-09-01
CN110248949A (zh) 2019-09-17
CN110248949B (zh) 2023-02-17
DK3571208T3 (da) 2021-05-10
US20190336515A1 (en) 2019-11-07
HRP20210663T1 (hr) 2021-05-28
MX393757B (es) 2025-03-24
US11154563B2 (en) 2021-10-26

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
ZA201905811B (en) Novel inhibitors
SG11202106520VA (en) Kif18a inhibitors
IL260217B (en) lsd1 driven
IL258159B (en) New proprotein inhibitors
ZA201705527B (en) TGF-ß INHIBITORS
ZA201907136B (en) Ip6k inhibitors
IL274523A (en) Immunoproteasome inhibitors
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
PT3571208T (pt) Inibidores do imunoproteassoma
IL265139B (en) Dopamine-b-hydroxylase inhibitors
GB201612860D0 (en) Inhibitors
IL276013A (en) pi4kiiibeta inhibitors
SG11202102379XA (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
GB201501004D0 (en) Inhibitors
IL274550A (en) Dopamine-B-hydroxylase inhibitors
LT3710457T (lt) Imunoproteasomos inhibitoriai
GB201520949D0 (en) Inhibitors
GB201721465D0 (en) Inhibitors
HK40033750A (en) Immunoproteasome inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201716867D0 (en) MAP4K4 inhibitors
GB201708002D0 (en) ß-Lactamase inhibitors